Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

Clinical trial NCT04635956 · UNKNOWN

Trial details

NCT number: NCT04635956
Sponsor: Lei Li
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Chemotherapy Anti-pd-1 Antibody Cervical Neuroendocrine Carcinoma Adverse Drug Event Recurrent Cervical Carcinoma Advanced Cervical Carcinoma Objective Response Rate

Start date: 2020-11-15
Primary completion: 2021-11-15
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.